753 related articles for article (PubMed ID: 25903941)
1. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
[TBL] [Abstract][Full Text] [Related]
2. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
[TBL] [Abstract][Full Text] [Related]
3. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
Camacho NP; Carroll P; Raggio CL
Calcif Tissue Int; 2003 May; 72(5):604-9. PubMed ID: 12574874
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Misof BM; Roschger P; Baldini T; Raggio CL; Zraick V; Root L; Boskey AL; Klaushofer K; Fratzl P; Camacho NP
Bone; 2005 Jan; 36(1):150-8. PubMed ID: 15664013
[TBL] [Abstract][Full Text] [Related]
5. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
Shi C; Hu B; Guo L; Cao P; Tian Y; Ma J; Chen Y; Wu H; Hu J; Deng L; Zhang Y; Yuan W
J Bone Miner Res; 2016 May; 31(5):1003-14. PubMed ID: 26679066
[TBL] [Abstract][Full Text] [Related]
6. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
McCarthy EA; Raggio CL; Hossack MD; Miller EA; Jain S; Boskey AL; Camacho NP
Pediatr Res; 2002 Nov; 52(5):660-70. PubMed ID: 12409511
[TBL] [Abstract][Full Text] [Related]
7. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.
Bargman R; Huang A; Boskey AL; Raggio C; Pleshko N
Connect Tissue Res; 2010 Apr; 51(2):123-31. PubMed ID: 20053133
[TBL] [Abstract][Full Text] [Related]
8. Infrared Spectroscopy-Determined Bone Compositional Changes Associated with Anti-Resorptive Treatment of the
Shanas N; Querido W; Oswald J; Jepsen K; Carter E; Raggio C; Pleshko N
Appl Spectrosc; 2022 Apr; 76(4):416-427. PubMed ID: 34643134
[TBL] [Abstract][Full Text] [Related]
9. Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
Shi C; Sun B; Ma C; Wu H; Chen R; He H; Zhang Y
Biomed Res Int; 2021; 2021():4243105. PubMed ID: 33506016
[TBL] [Abstract][Full Text] [Related]
10. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.
Delos D; Yang X; Ricciardi BF; Myers ER; Bostrom MP; Camacho NP
J Orthop Res; 2008 Feb; 26(2):153-64. PubMed ID: 17729310
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta.
Berman AG; Wallace JM; Bart ZR; Allen MR
Matrix Biol; 2016; 52-54():19-28. PubMed ID: 26707242
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
[TBL] [Abstract][Full Text] [Related]
13. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
Camacho NP; Raggio CL; Doty SB; Root L; Zraick V; Ilg WA; Toledano TR; Boskey AL
Calcif Tissue Int; 2001 Aug; 69(2):94-101. PubMed ID: 11683430
[TBL] [Abstract][Full Text] [Related]
14. Mineral changes in a mouse model of osteogenesis imperfecta detected by Fourier transform infrared microscopy.
Camacho NP; Landis WJ; Boskey AL
Connect Tissue Res; 1996; 35(1-4):259-65. PubMed ID: 9084664
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
[TBL] [Abstract][Full Text] [Related]
16. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.
King D; Jarjoura D; McEwen HA; Askew MJ
J Bone Miner Res; 2005 Jun; 20(6):987-93. PubMed ID: 15883639
[TBL] [Abstract][Full Text] [Related]
18. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
[TBL] [Abstract][Full Text] [Related]
19. The material basis for reduced mechanical properties in oim mice bones.
Camacho NP; Hou L; Toledano TR; Ilg WA; Brayton CF; Raggio CL; Root L; Boskey AL
J Bone Miner Res; 1999 Feb; 14(2):264-72. PubMed ID: 9933481
[TBL] [Abstract][Full Text] [Related]
20. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
